US 12208084 B1Patent grantUnited States

Apoptosis and Inflammation Research Compound

Official patent title

Method of treating cancer in a subject

Arabic title: طريقة لعلاج السرطان لدى شخص

Invention

Problem

Cancer, including triple-negative breast cancer, continues to require additional therapeutic candidates, but any new compound must be evaluated for selectivity, toxicity, exposure, and clinical benefit.

Why it matters

Compounds that can be studied against apoptosis and inflammation pathways may expand preclinical options, although patent claims alone do not establish treatment efficacy or safety.

Approach

The patent claims administration of a compound of Formula I, or a pharmaceutically acceptable salt, for cancer or inflammation and defines substitution options, dosage ranges, routes, and selected gene-expression targets.

Who may benefit

Potential beneficiaries include medicinal-chemistry teams, oncology and inflammation researchers, pharmaceutical developers, formulation scientists, and technology-transfer partners assessing early therapeutic assets.

Potential value

The disclosure provides a chemical genus, a specific Compound II embodiment, claimed cancer and inflammation indications, named molecular pathways, and multiple formulation and administration options for preclinical evaluation.

Background

Cancer therapies can damage healthy cells and cause serious adverse effects, while triple-negative breast cancer has fewer targeted treatment options than several other breast-cancer subtypes. Apoptosis involves regulators such as p53, BAX, caspases, and BCL-2, and inflammatory mediators including COX-2, IL-6, and IL-1β can be relevant to disease research. The patent proposes a substituted compound family for modulating selected pathways. The assigned evidence states treatment methods and pharmaceutical compositions but does not document animal efficacy, human trials, safety, pharmacokinetics, or regulatory approval.

Technology overview

Formula I permits independent choices for R1–R4, R5A–R7A, and R5B–R7B from hydrogen, halogen, nitro, cyano, hydroxyl, alkoxy, and optionally substituted alkyl, cycloalkyl, arylalkyl, or aryl groups. Claims include Compound II, several cancer types, apoptosis-associated upregulation of p53, BAX, and Caspases 3, 6, 8, or 9, and downregulation of BCL-2, MMP2, or MMP9. Claimed administration spans 0.1–1000 mg/kg and several routes, with pharmaceutically acceptable carriers or excipients.

Potential applications

Potential use as a compound family for preclinical oncology screening.
Potential use in laboratory studies of apoptosis-associated gene regulation.
Potential use in preclinical inflammation-pathway research involving COX-2, IL-6, or IL-1β.
Potential use in pharmaceutical formulation and route-of-administration studies.

Evidence-supported advantages

Defines a broad substituted chemical family plus a specific Compound II embodiment.
Names cancer types and apoptosis-associated genes within the claimed treatment scope.
Includes a separate inflammation claim linked to COX-2, IL-6, and IL-1β.
Covers multiple administration routes and carrier or excipient categories.

Development stage

Patent publication; development stage not independently verified.

Commercial opportunity

The claims may provide a starting point for licensing into a discovery-stage oncology or inflammation program. Progress would require structure confirmation, synthesis and analytical data, reproducible cell studies, selectivity and toxicology, pharmacokinetics, formulation, animal efficacy, dose justification, clinical trials, manufacturing controls, and regulatory review.

Patent classifications

WIPO IPC

A61K31/4035Preparations for medical, dental or toiletry purposes
A61P29/00Specific therapeutic activity of chemical compounds or medicinal preparations

CPC

A61P35/00Specific therapeutic activity of chemical compounds or medicinal preparations
A61P29/00Specific therapeutic activity of chemical compounds or medicinal preparations
A61K31/4035Preparations for medical, dental or toiletry purposes

Inventors

First inventorTarek Ahmed Yousef
InventorSaad Shaaban
InventorAhmed A. Al-Karmalawy
InventorAyman Abo Elmaaty
InventorMarwa Sharaky

Keywords

Formula I
Compound II
cancer treatment
triple-negative breast cancer
apoptosis
inflammation
gene regulation
pharmaceutical composition

Patent document and drawings

The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.